Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
2015 ◽
Vol 15
(6)
◽
pp. 645-653
◽
Keyword(s):
Phase 3
◽